A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors

Pashtoon Murtaza Kasi, Catherine L. Maige, Faisal Shahjehan, Jessica M. Rodgers, Debora L. Aloszka, Ashton Ritter, Margaret L. Andrus, Jessica M. Mcmillan, Kabir Mody, Akash Sharma, Manoj K. Jain

Research output: Contribution to journalArticle

Abstract

Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: A multidisciplinary, structured PRRT process model was established. Over the last 9 months, meetings were held bi-weekly to discuss the logistics of clinical trials. Meetings are still held regularly at the Mayo Clinic Florida to discuss plans regarding commercially available PRRT treatments. The process model has evolved as we have treated patients on both clinical trials and commercial treatments. Results: An effective process model was formulated. We had 5 patients on our Expanded Access Program (EAP) clinical trial. Our ability to be a part of the EAP allowed us to understand the mechanics of how to treat these patients, and what was involved before it became commercially available. Since commercial availability of the 177Lu-Dotatate, more than 50 treatments (>20 patients) have already been completed, with several new patients getting started on treatment every week. Our nuclear medicine department receives continual requests to schedule new patients for PRRT. This can be attributed to our streamlined approach in delivering PRRT to our patients. Conclusion: A thorough procedural approach was formulated to provide patients with PRRT. Experiences and challenges led to refinement, which has allowed the process to advance. This development could lead to better patient outcomes, treatment efficiency, and a reference standard for other institutions trying to develop this at their location.

Original languageEnglish (US)
Article number663
JournalFrontiers in Oncology
Volume9
Issue numberJAN
DOIs
StatePublished - Jan 1 2019

Fingerprint

Peptide Receptors
Neuroendocrine Tumors
Radioisotopes
Therapeutics
Clinical Trials
Lutetium
Somatostatin Receptors
Nuclear Medicine
Mechanics
Appointments and Schedules

Keywords

  • Lu-Dotatate
  • Lutathera
  • NET
  • Neuroendocrine tumor
  • Peptide receptor radionuclide therapy
  • PRRT
  • Somatostatin receptor
  • Theranostics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kasi, P. M., Maige, C. L., Shahjehan, F., Rodgers, J. M., Aloszka, D. L., Ritter, A., ... Jain, M. K. (2019). A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors. Frontiers in Oncology, 9(JAN), [663]. https://doi.org/10.3389/fonc.2018.00663

A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors. / Kasi, Pashtoon Murtaza; Maige, Catherine L.; Shahjehan, Faisal; Rodgers, Jessica M.; Aloszka, Debora L.; Ritter, Ashton; Andrus, Margaret L.; Mcmillan, Jessica M.; Mody, Kabir; Sharma, Akash; Jain, Manoj K.

In: Frontiers in Oncology, Vol. 9, No. JAN, 663, 01.01.2019.

Research output: Contribution to journalArticle

Kasi, PM, Maige, CL, Shahjehan, F, Rodgers, JM, Aloszka, DL, Ritter, A, Andrus, ML, Mcmillan, JM, Mody, K, Sharma, A & Jain, MK 2019, 'A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors', Frontiers in Oncology, vol. 9, no. JAN, 663. https://doi.org/10.3389/fonc.2018.00663
Kasi, Pashtoon Murtaza ; Maige, Catherine L. ; Shahjehan, Faisal ; Rodgers, Jessica M. ; Aloszka, Debora L. ; Ritter, Ashton ; Andrus, Margaret L. ; Mcmillan, Jessica M. ; Mody, Kabir ; Sharma, Akash ; Jain, Manoj K. / A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors. In: Frontiers in Oncology. 2019 ; Vol. 9, No. JAN.
@article{7cc2d7833e014035a88237a822647adc,
title = "A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors",
abstract = "Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: A multidisciplinary, structured PRRT process model was established. Over the last 9 months, meetings were held bi-weekly to discuss the logistics of clinical trials. Meetings are still held regularly at the Mayo Clinic Florida to discuss plans regarding commercially available PRRT treatments. The process model has evolved as we have treated patients on both clinical trials and commercial treatments. Results: An effective process model was formulated. We had 5 patients on our Expanded Access Program (EAP) clinical trial. Our ability to be a part of the EAP allowed us to understand the mechanics of how to treat these patients, and what was involved before it became commercially available. Since commercial availability of the 177Lu-Dotatate, more than 50 treatments (>20 patients) have already been completed, with several new patients getting started on treatment every week. Our nuclear medicine department receives continual requests to schedule new patients for PRRT. This can be attributed to our streamlined approach in delivering PRRT to our patients. Conclusion: A thorough procedural approach was formulated to provide patients with PRRT. Experiences and challenges led to refinement, which has allowed the process to advance. This development could lead to better patient outcomes, treatment efficiency, and a reference standard for other institutions trying to develop this at their location.",
keywords = "Lu-Dotatate, Lutathera, NET, Neuroendocrine tumor, Peptide receptor radionuclide therapy, PRRT, Somatostatin receptor, Theranostics",
author = "Kasi, {Pashtoon Murtaza} and Maige, {Catherine L.} and Faisal Shahjehan and Rodgers, {Jessica M.} and Aloszka, {Debora L.} and Ashton Ritter and Andrus, {Margaret L.} and Mcmillan, {Jessica M.} and Kabir Mody and Akash Sharma and Jain, {Manoj K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2018.00663",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors

AU - Kasi, Pashtoon Murtaza

AU - Maige, Catherine L.

AU - Shahjehan, Faisal

AU - Rodgers, Jessica M.

AU - Aloszka, Debora L.

AU - Ritter, Ashton

AU - Andrus, Margaret L.

AU - Mcmillan, Jessica M.

AU - Mody, Kabir

AU - Sharma, Akash

AU - Jain, Manoj K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: A multidisciplinary, structured PRRT process model was established. Over the last 9 months, meetings were held bi-weekly to discuss the logistics of clinical trials. Meetings are still held regularly at the Mayo Clinic Florida to discuss plans regarding commercially available PRRT treatments. The process model has evolved as we have treated patients on both clinical trials and commercial treatments. Results: An effective process model was formulated. We had 5 patients on our Expanded Access Program (EAP) clinical trial. Our ability to be a part of the EAP allowed us to understand the mechanics of how to treat these patients, and what was involved before it became commercially available. Since commercial availability of the 177Lu-Dotatate, more than 50 treatments (>20 patients) have already been completed, with several new patients getting started on treatment every week. Our nuclear medicine department receives continual requests to schedule new patients for PRRT. This can be attributed to our streamlined approach in delivering PRRT to our patients. Conclusion: A thorough procedural approach was formulated to provide patients with PRRT. Experiences and challenges led to refinement, which has allowed the process to advance. This development could lead to better patient outcomes, treatment efficiency, and a reference standard for other institutions trying to develop this at their location.

AB - Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: A multidisciplinary, structured PRRT process model was established. Over the last 9 months, meetings were held bi-weekly to discuss the logistics of clinical trials. Meetings are still held regularly at the Mayo Clinic Florida to discuss plans regarding commercially available PRRT treatments. The process model has evolved as we have treated patients on both clinical trials and commercial treatments. Results: An effective process model was formulated. We had 5 patients on our Expanded Access Program (EAP) clinical trial. Our ability to be a part of the EAP allowed us to understand the mechanics of how to treat these patients, and what was involved before it became commercially available. Since commercial availability of the 177Lu-Dotatate, more than 50 treatments (>20 patients) have already been completed, with several new patients getting started on treatment every week. Our nuclear medicine department receives continual requests to schedule new patients for PRRT. This can be attributed to our streamlined approach in delivering PRRT to our patients. Conclusion: A thorough procedural approach was formulated to provide patients with PRRT. Experiences and challenges led to refinement, which has allowed the process to advance. This development could lead to better patient outcomes, treatment efficiency, and a reference standard for other institutions trying to develop this at their location.

KW - Lu-Dotatate

KW - Lutathera

KW - NET

KW - Neuroendocrine tumor

KW - Peptide receptor radionuclide therapy

KW - PRRT

KW - Somatostatin receptor

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85063303850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063303850&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00663

DO - 10.3389/fonc.2018.00663

M3 - Article

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JAN

M1 - 663

ER -